AV Junction Ablation or Optimal Medical Treatment in PatiEnts With Cardiac Resynchronization Therapy and Permanent Atrial Fibrillation

Status: Recruiting
Intervention Type: Procedure, Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

A study comparing atrioventricular junction ablation (AVJA) versus continued optimum medical rate control in patients with cardiac resynchronization therapy (CRT) and atrial fibrillation (AF) with suboptimal heart rate control on optimum medication.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: f
View:

• Treatment with CRT using either a biventricular pacemaker/defibrillator or conduction system pacemaker (\>6 months)

• Diagnosis of AF and classified as: permanent AF or recurrent persistent AF, requiring emergency visits and/or hospitalizations (at least one in recent year)

• Optimized HF medical treatment and rate control medication

• BiVP% + ventricular premature complex (VPC%) \<99% and \>85% during the minimum period of 1 month while already on optimum medical therapy (applicable only for patients with permanent AF)

• Age \>18 and \<85 years

• Signed informed consent

Contact Information
Primary
Jiří Hynčica
jiri.hyncica@fno.cz
0042059737
Time Frame
Start Date: 2023-04-01
Estimated Completion Date: 2029-03-31
Participants
Target number of participants: 480
Treatments
Experimental: Atrioventricular junction ablation (AVJA) in patients with cardiac resynchronization therapy (CRT)
Patients with cardiac resynchronization therapy (CRT) randomized in this arm will undergo atrioventricular junction ablation.
Active_comparator: Optimal medication treatment in patients with cardiac resynchronization therapy (CRT)
Patients with cardiac resynchronization therapy (CRT) randomized in this arm will receive optimal medication treatment.
Related Therapeutic Areas
Atrial Fibrillation
Sponsors
Leads: University Hospital Ostrava

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

Rate Control Efficacy in Atrial Fibrillation With Rheumatic Mitral Stenosis: Assessing Clinical Outcomes of Lenient Versus Strict Heart Rate Control in Reducing Hospitalizations, Improving Quality of Life, and Enhancing Functional Capacity

Rate Control Efficacy in Atrial Fibrillation With Rheumatic Mitral Stenosis: Assessing Clinical Outcomes of Lenient Versus Strict Heart Rate Control in Reducing Hospitalizations, Improving Quality of Life, and Enhancing Functional Capacity

Enrollment Status: Recruiting
Publish Date: May 10, 2024
Intervention Type: Other
Study Phase: Not Applicable

Device-based Rate Versus Rhythm Control Treatment in Patients With Symptomatic Recent-onset Atrial Fibrillation in the Emergency Department (RACE 9 OBSERVE-AF)

Device-based Rate Versus Rhythm Control Treatment in Patients With Symptomatic Recent-onset Atrial Fibrillation in the Emergency Department (RACE 9 OBSERVE-AF)

Enrollment Status: Recruiting
Publish Date: May 22, 2024
Intervention Type: Other
Study Phase: Not Applicable

Lenient Rate Control Versus Strict Rate Control for Atrial Fibrillation. The Danish Atrial Fibrillation (DanAF) Randomised Clinical Trial

Lenient Rate Control Versus Strict Rate Control for Atrial Fibrillation. The Danish Atrial Fibrillation (DanAF) Randomised Clinical Trial

Enrollment Status: Recruiting
Publish Date: March 16, 2022
Intervention Type: Other
Study Phase: Not Applicable
View All